Related Experiment Video
Updated: May 6, 2026

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
Network pharmacology and Mendelian randomization analysis of Xiao Bi decoction in treating psoriasis
Wentao Hu1, Yifang Jiang2, Jie Wang1
1Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Abstract:
Psoriasis is a chronic autoimmune disease marked by excessive keratinocyte growth and immune issues. Xiao Bi decoction (XBT), a traditional Chinese formula, has shown effective for treating psoriasis. This study integrated network pharmacology and Mendelian randomization analysis to explore the therapeutic mechanism of XBT and validate causal relationships between its active components, potential targets, and psoriasis outcomes. The results showed that XBT contains 171 active components, of which the top 5 active components with the highest degree values were quercetin, dihydrobaicalin _qt, Pyrethrin II, Kinobeon A, and Baicalein; the main core targets of XBT were tumor necrosis factor, interleukin (IL)-6, glyceraldehyde-3-phosphate dehydrogenase, AKT1, and IL-1B. These core components and core targets can be better molecular docking, and Mendelian randomization analysis showed that there is a causal relationship between the reduced level of IL-6 and the increased risk of psoriasis. These results provide novel insights into the molecular mechanisms and scientific validation of XBT's use in psoriasis.
More Related Videos
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets